GlassScriptPhysician profile
David R Willingham
NPI 1770928145
$9,306.45
in general payments reported to CMS, 2019-2025
55 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $1,049 · 2021: $1,349 · 2022: $834 · 2023: $1,467 · 2024: $1,280 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,179.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,046.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,018.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.25 | 2019-2025 | Jardiance |
| Amgen INC. | $736.25 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $556.89 | 2019-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $544.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $462.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $380.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $377.86 | 2019-2025 | Airsupra |
| Abbott Laboratories | $356.34 | 2019-2025 | Proclaim, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $327.78 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Allergan, INC. | $317.15 | 2019-2020 | |
| Astellas Pharma US INC | $263.40 | 2019-2024 | Veozah |
| Esperion Therapeutics, INC. | $178.43 | 2020-2021 | |
| Mylan Specialty L.P. | $173.92 | 2020-2023 | Yupelri |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Willingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.